- Home
- EPAM vs HALO Comparison
EPAM vs HALO Comparison
Compare EPAM & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAM
- HALO
- Stock Information
- Founded
- EPAM 1993
- HALO 1998
- Country
- EPAM United States
- HALO United States
- Employees
- EPAM N/A
- HALO N/A
- Industry
- EPAM EDP Services
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPAM Technology
- HALO Health Care
- Exchange
- EPAM Nasdaq
- HALO Nasdaq
- Market Cap
- EPAM 8.2B
- HALO 7.4B
- IPO Year
- EPAM 2012
- HALO N/A
- Fundamental
- Price
- EPAM $186.90
- HALO $50.23
- Analyst Decision
- EPAM Buy
- HALO Buy
- Analyst Count
- EPAM 16
- HALO 9
- Target Price
- EPAM $229.00
- HALO $63.78
- AVG Volume (30 Days)
- EPAM 702.9K
- HALO 2.6M
- Earning Date
- EPAM 05-08-2025
- HALO 05-06-2025
- Dividend Yield
- EPAM N/A
- HALO N/A
- EPS Growth
- EPAM N/A
- HALO 55.40
- EPS
- EPAM 7.15
- HALO 3.76
- Revenue
- EPAM $4,864,167,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- EPAM $14.70
- HALO $24.79
- Revenue Next Year
- EPAM $7.82
- HALO $22.65
- P/E Ratio
- EPAM $26.15
- HALO $13.36
- Revenue Growth
- EPAM 4.72
- HALO 25.64
- 52 Week Low
- EPAM $138.15
- HALO $41.28
- 52 Week High
- EPAM $269.00
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- EPAM 69.19
- HALO 34.42
- Support Level
- EPAM $156.21
- HALO $58.38
- Resistance Level
- EPAM $185.61
- HALO $69.94
- Average True Range (ATR)
- EPAM 4.78
- HALO 3.30
- MACD
- EPAM 4.79
- HALO -0.27
- Stochastic Oscillator
- EPAM 92.63
- HALO 9.30
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenue. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.